Microbix Biosystems Inc. (MBXBF)
- Previous Close
0.2483 - Open
0.2680 - Bid --
- Ask --
- Day's Range
0.2507 - 0.2680 - 52 Week Range
0.1710 - 0.3360 - Volume
6,500 - Avg. Volume
4,834 - Market Cap (intraday)
35.454M - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
12.90 - EPS (TTM)
0.0200 - Earnings Date Aug 8, 2024 - Aug 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures diagnostic-test products, such as test-controls under the QAPs brand; viral transport medium for collection of patient samples to test for pathogens including virus causing the COVID-19 disease under the DxTM brand; Kinlytic, a biologic thrombolytic drug used to treat blood clots; and antigen products. Microbix Biosystems Inc. was founded in 1988 and is headquartered in Mississauga, Canada.
www.microbix.comRecent News: MBXBF
Performance Overview: MBXBF
Trailing total returns as of 5/15/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MBXBF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MBXBF
Valuation Measures
Market Cap
32.14M
Enterprise Value
27.68M
Trailing P/E
12.72
Forward P/E
16.98
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.09
Price/Book (mrq)
1.71
Enterprise Value/Revenue
1.69
Enterprise Value/EBITDA
6.43
Financial Highlights
Profitability and Income Statement
Profit Margin
16.57%
Return on Assets (ttm)
1.87%
Return on Equity (ttm)
14.66%
Revenue (ttm)
22.42M
Net Income Avi to Common (ttm)
3.72M
Diluted EPS (ttm)
0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
12.78M
Total Debt/Equity (mrq)
24.53%
Levered Free Cash Flow (ttm)
-794.45k
Research Analysis: MBXBF
Company Insights: MBXBF
MBXBF does not have Company Insights